JPS63149561A - Analysis of prostaglandin - Google Patents
Analysis of prostaglandinInfo
- Publication number
- JPS63149561A JPS63149561A JP29485886A JP29485886A JPS63149561A JP S63149561 A JPS63149561 A JP S63149561A JP 29485886 A JP29485886 A JP 29485886A JP 29485886 A JP29485886 A JP 29485886A JP S63149561 A JPS63149561 A JP S63149561A
- Authority
- JP
- Japan
- Prior art keywords
- liquid
- solvent
- ethyl acetate
- solution
- adam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 16
- XXDVOJKRZBNPFN-UHFFFAOYSA-N 9-[(e)-diazomethyl]anthracene Chemical compound C1=CC=C2C(C=[N+]=[N-])=C(C=CC=C3)C3=CC2=C1 XXDVOJKRZBNPFN-UHFFFAOYSA-N 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 4
- 238000001212 derivatisation Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000002198 insoluble material Substances 0.000 claims 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 abstract description 15
- 239000012535 impurity Substances 0.000 abstract description 11
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、プロスタグランディンの分析方法に係り、特
に液体クロマトグラフを用いた生体試料中のプロスタグ
ランディンの分析方法に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a method for analyzing prostaglandins, and particularly to a method for analyzing prostaglandins in a biological sample using a liquid chromatograph.
プロスタグランディンは、生体機能をコントロールする
重要なホルモン様機能を有する物質であり、これを含有
する生体組織又は生体液を処理して液体クロマトグラフ
で分析することが知られている。Prostaglandins are substances that have important hormone-like functions that control biological functions, and it is known that biological tissues or fluids containing prostaglandins can be processed and analyzed using liquid chromatography.
特開昭61−202164には、生体試料に、あらかじ
めmmした9−アンスリルジアゾメタンC以下ADAM
と略称する)を作用させてプロスタグランディン(以下
PGと略称する)を誘導体化した後、各種の前処理を施
してから液体クロマトグラフで分析する方法が示されて
いる。JP-A No. 61-202164 discloses that 9-anthryldiazomethane C or less ADAM, which has been pre-prepared to mm, is added to biological samples.
A method is disclosed in which prostaglandins (hereinafter abbreviated as PG) are derivatized by the action of PG (hereinafter abbreviated as PG), subjected to various pretreatments, and then analyzed with a liquid chromatograph.
従来は、PGを含む試料と反応させる前にADAMを精
製していた。というのは、市販されているADAMは多
くの共存物質を有しており、そのままでは分析試薬とし
て適用できないからである。一方、ADAM自体は不安
定で変質しやすく、試料中のPGも急速な経時変化を起
こしやすいという問題がある。しかし、PGがADAM
と反応して生じた誘導体は、経時的に安定であり、蛍光
性を有するので、クロマトグラフ分針によって蛍光を検
出して定量することができるので、実用的に利用されて
いる。Conventionally, ADAM was purified before reacting with a sample containing PG. This is because commercially available ADAM contains many coexisting substances and cannot be used as an analytical reagent as it is. On the other hand, there are problems in that ADAM itself is unstable and easily deteriorates, and PG in the sample also tends to change rapidly over time. However, PG is ADAM
The derivative produced by the reaction with is stable over time and has fluorescence, so the fluorescence can be detected and quantified with a chromatographic minute hand, so it is used practically.
ADAMt−PGとの反応の前に精製すると、精製操作
の間に変質してしまうという問題があった。When purified before the reaction with ADAMt-PG, there was a problem in that the quality deteriorated during the purification operation.
さらに従来の方法によれば、不純物を十分に除去しきれ
ないという問題があった。Furthermore, conventional methods have the problem of not being able to sufficiently remove impurities.
本発明の目的は、ADAMの利用効率が高く、PGの変
性も少なくできるPGの分析方法を提供することにある
。An object of the present invention is to provide a method for analyzing PG that has high ADAM utilization efficiency and can reduce PG denaturation.
本発明は、プロスタグランディンを含む試料に酢酸エチ
ルを溶媒とした9−アンスリルジアゾメタン溶液を混合
して上記プロスタグランディンを誘導体化し、この液の
溶媒を揮散せしめて除去した後、残留物をメタノール又
はアセトニトリルで溶解し、この溶解液を冷却して不溶
物を析出させ、この析出不溶物を分別除去した液の溶媒
を揮散せしめて除去し、残留物を酢酸エチルで溶解し、
この溶解液をゲルパーミェーションカラムを通して低分
子物質を分離除去し、上記ゲルパーミェーションカラム
からの回収液を逆相分配カラムを備えた液体クロマトグ
ラフで分析することを特徴とする。The present invention derivatizes the prostaglandin by mixing a sample containing prostaglandin with a solution of 9-anthryldiazomethane using ethyl acetate as a solvent, and removes the solvent by volatilizing the solution, and then removes the residue. Dissolve in methanol or acetonitrile, cool this solution to precipitate insoluble matter, remove the precipitated insoluble matter by evaporating the solvent of the liquid, and dissolve the residue in ethyl acetate,
The method is characterized in that the dissolved solution is passed through a gel permeation column to separate and remove low-molecular substances, and the recovered solution from the gel permeation column is analyzed using a liquid chromatograph equipped with a reverse phase distribution column.
本発明では、冷却保存してあったADAMを最初に精製
するのではなく、精製前にまずPGと反応させPGの誘
導体を形成する。この反応時にはADAM溶液の溶媒と
して酢酸エチルを使用し。In the present invention, instead of first purifying ADAM that has been stored in cold storage, it is first reacted with PG to form a PG derivative before purification. During this reaction, ethyl acetate was used as a solvent for the ADAM solution.
PGを抽出させる。Let PG be extracted.
次に、溶媒除去した残留物をメタノール又はアセトニト
リルで溶解した液を低温(−20’C)に冷却して夾雑
物を析出させ、析出物を遠心分離法又は濾過法によって
除去する。これによって高分子不純物が除去される。Next, a solution obtained by dissolving the solvent-removed residue in methanol or acetonitrile is cooled to a low temperature (-20'C) to precipitate impurities, and the precipitate is removed by centrifugation or filtration. This removes polymeric impurities.
次いで、再び溶媒除去し、残留物酢酸エチルで溶解した
液をゲルパーミェーションカラム(以下GPCカラムと
称す)に通し、初期に溶出する溶は排出し、残りの溶出
液を回収する。この回収液では低分子不純物が除去され
ている。かくして得たPG誘導体を含む液を逆相分配カ
ラムを備えた液体クロマトグラフで分析する。Next, the solvent is removed again, and the residue dissolved in ethyl acetate is passed through a gel permeation column (hereinafter referred to as GPC column), the initially eluted solution is discharged, and the remaining eluate is collected. Low molecular impurities have been removed from this recovered liquid. The liquid containing the PG derivative thus obtained is analyzed using a liquid chromatograph equipped with a reverse phase distribution column.
溶媒として酢酸エチルを用いることにより、通常の溶媒
を用いる場合に比べて、ADAMの変性を低減でき、水
溶性成分との分離性も良くなる。By using ethyl acetate as a solvent, denaturation of ADAM can be reduced and separation from water-soluble components can be improved, compared to the case where a normal solvent is used.
本発明の一実施例の分析操作を第1図に示す。 FIG. 1 shows an analytical operation according to an embodiment of the present invention.
生体試料には、蛋白質を除くための前処理を施す。Biological samples are pretreated to remove proteins.
血清試料または生体組織の1m12を限外濾過法にて処
理し、濾液を回収する。この限外濾過器には、アミコン
社製のセントリーフローCF 25を用いた。1 ml of serum sample or biological tissue is treated by ultrafiltration and the filtrate is collected. As this ultrafilter, Sentry Flow CF 25 manufactured by Amicon was used.
次に、PGを含む濾液1 m Qに、酢酸エチルで溶解
したA D A M試薬液(0,1%)1m+2を加え
て3分間振盪し、次いで遠心分離器に設置して1000
Gの重力にて遠心分離する。ADAMとの反応によって
生成されたPG誘導体は、酢酸エチル液層内に溶解され
ている。この液層を試験管内に取り出し、温浴上で窒素
ガスを通気させながら、溶媒を揮散せしめ除去する。Next, 1 m + 2 of ADAM reagent solution (0.1%) dissolved in ethyl acetate was added to 1 m Q of the filtrate containing PG, shaken for 3 minutes, and then placed in a centrifuge at 1000
Centrifuge at G gravity. The PG derivative produced by reaction with ADAM is dissolved in the ethyl acetate liquid layer. This liquid layer is taken out into a test tube, and the solvent is volatilized and removed while blowing nitrogen gas over a hot bath.
乾固された残留物を、1mflのメタノール又はアセト
ニトリルに溶解した後、−20℃にて12時間冷却し、
高分子不純物を析出させる。次にこのけん濁液を遠心分
離器にかけて、析出物を分別し、液層を取り出す。この
場合、遠心分離の代りに濾過を行ってもよい。The dried residue was dissolved in 1 mfl of methanol or acetonitrile, and then cooled at -20°C for 12 hours.
Precipitates polymeric impurities. Next, this suspension is centrifuged to separate the precipitate and the liquid layer is taken out. In this case, filtration may be performed instead of centrifugation.
取り出された液を試験管内に取り出し、再度温浴上で窒
素ガスを通気させながら、溶媒を揮散せしめて除去し乾
固する。この残留物を100μΩの酢酸エチルで溶解し
、この溶液をGPCカラムに導入し、クロロホルムを溶
離液として分離し、GPCカラムからの初期の溶出液を
排出して残りを回収する。GPCカラムとしては1日立
化成社のGELPADK−R420を用いた。これによ
り、低分子不純物を除去する。The taken out liquid is taken out into a test tube, and the solvent is volatilized and removed while nitrogen gas is passed through the hot bath again, and the test tube is dried. The residue is dissolved in 100 μΩ ethyl acetate, the solution is introduced into a GPC column and separated using chloroform as eluent, the initial eluate from the GPC column is drained and the remainder is collected. As a GPC column, GELPADK-R420 manufactured by Hitachi Chemical Co., Ltd. was used. This removes low molecular weight impurities.
このようにして分取液として得られた液には。The liquid obtained as a preparative liquid in this way.
従来のものより大幅に不純物が減少されている。Impurities are significantly reduced compared to conventional products.
この分取液を逆相分配カラムを備えた液体クロマトグラ
フで分離分析し、誘導体化されたPGのクロマトグラム
を得る。検出器として蛍光光度計を用いる。This fractionated liquid is separated and analyzed using a liquid chromatograph equipped with a reverse phase distribution column to obtain a chromatogram of derivatized PG. A fluorometer is used as a detector.
第2図には従来法に基づいて得られたクロマトグラムを
示し、第3図には同じ試料について本発明に基づいて得
られたクロマトグラムを示す、ピーク1はトロンボキサ
ンBz(TXBz)であり。Figure 2 shows a chromatogram obtained based on the conventional method, and Figure 3 shows a chromatogram obtained for the same sample based on the present invention. Peak 1 is thromboxane Bz (TXBz). .
ピーク2はP G E zであり、ピーク3はP G
F zαであり、ピーク4は6−ケトPGFzαであり
。Peak 2 is P G E z and peak 3 is P G
Fzα, and peak 4 is 6-keto PGFzα.
ピーク5はP G E sである。本発明に基づけば、
不純物によるピークが減少されていることが理解される
。Peak 5 is P G E s. Based on the present invention,
It is understood that the peaks due to impurities are reduced.
上述した実施例によれば、試料の前処理時のプロスタグ
ランディンの変性を少なくでき、また、ラベル化剤の精
製は1反応後に行なうことができるので、安定した誘導
体化が可能である。特にプロスタグランディンおよびA
DAM共にそれ自体不安定であるが、誘導体化物は安定
であることから水沫は有効である。クロマトグラムもA
D A M試薬の高分子領域はメタノールで、低分子
領域はGPC法で除去することにより、定量精度が向上
した。According to the above embodiments, denaturation of prostaglandin during sample pretreatment can be reduced, and the labeling agent can be purified after one reaction, so stable derivatization is possible. Especially prostaglandins and A
Both DAM and DAM are unstable in themselves, but the derivatized products are stable, so water droplets are effective. Chromatogram is also A
The quantitative accuracy was improved by removing the high molecular region of the DAM reagent with methanol and the low molecular region with GPC method.
発明によれば、A D A Mを変質が進む前に反応に
利用でき、PGの測定精度を向上することかできる。According to the invention, ADAM can be used for reaction before deterioration progresses, and the accuracy of PG measurement can be improved.
第1図は1本発明の一実施例の分析操作を示す図、第2
は従来法によるクロマトグラムを示す図。
第3図は本発明に基づくクロマトグラムを示す図 、−
1、fl
である。 、
−・・1)・−一 ′Fig. 1 is a diagram showing the analytical operation of one embodiment of the present invention;
is a diagram showing a chromatogram obtained by a conventional method. FIG. 3 is a diagram showing a chromatogram based on the present invention.
1, fl. ,
−・・1)・−1 ′
Claims (1)
体クロマトグラフで分析する方法において、プロスタグ
ランデインを含む試料に酢酸エチルを溶媒とした9−ア
ンスリルジアゾメタン溶液を混合して上記プロスタグラ
ンデインを誘導体化し、この液の溶媒を揮散せしめて除
去した後、残留物をメタノール又はアセトニトリルで溶
解し、この溶解液を冷却して不溶物を析出させ、この析
出不溶物を分別除去した液の溶媒を揮散せしめて除去し
、残留物を酢酸エチルで溶解し、この溶解液をゲルパー
ミェーションカラムを通して低分子物質を分離除去し、
上記ゲルパーミェーションカラムからの回収液を逆相分
配カラムを備えた液体クロマトグラフで分析することを
特徴とするプロスタグランデインの分析方法。1. In a method of analyzing prostaglandin in biological tissues or fluids using liquid chromatography, the above-mentioned prostaglandin is extracted by mixing a 9-anthryldiazomethane solution using ethyl acetate as a solvent with a sample containing prostaglandin. After derivatization and removing the solvent of this liquid by volatilization, the residue is dissolved in methanol or acetonitrile, this solution is cooled to precipitate insoluble materials, and the solvent of the liquid from which the precipitated insoluble materials are separated is removed. The residue was dissolved in ethyl acetate, and the solution was passed through a gel permeation column to separate and remove low-molecular substances.
A method for analyzing prostaglandin, comprising analyzing the liquid recovered from the gel permeation column using a liquid chromatograph equipped with a reversed phase distribution column.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29485886A JPS63149561A (en) | 1986-12-12 | 1986-12-12 | Analysis of prostaglandin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29485886A JPS63149561A (en) | 1986-12-12 | 1986-12-12 | Analysis of prostaglandin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63149561A true JPS63149561A (en) | 1988-06-22 |
Family
ID=17813162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29485886A Pending JPS63149561A (en) | 1986-12-12 | 1986-12-12 | Analysis of prostaglandin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63149561A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040357A1 (en) * | 1996-04-19 | 1997-10-30 | Dainippon Seiki Co., Ltd. | Automatic extracting equipment and automatic concentration measuring equipment for component substance in liquid sample |
JP2007109716A (en) * | 2005-10-11 | 2007-04-26 | Nippon Mektron Ltd | Process for producing printed board having cable portion |
-
1986
- 1986-12-12 JP JP29485886A patent/JPS63149561A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040357A1 (en) * | 1996-04-19 | 1997-10-30 | Dainippon Seiki Co., Ltd. | Automatic extracting equipment and automatic concentration measuring equipment for component substance in liquid sample |
JP2007109716A (en) * | 2005-10-11 | 2007-04-26 | Nippon Mektron Ltd | Process for producing printed board having cable portion |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Harfenist et al. | Countercurrent distribution studies with insulin | |
Rembold et al. | Convenient method for the determination of picomole amounts of juvenile hormone | |
US5578204A (en) | Apparatus for recovery and buffer exchange and/or concentration of dissolved macromolecules from a mixture of macromolecules | |
JPS63149561A (en) | Analysis of prostaglandin | |
CN108445116B (en) | Pretreatment method for free oxytocin in organism liquid sample | |
EP1181537A1 (en) | Destructible surfactants and uses thereof | |
Metrione et al. | Subunit structure of dipeptidyl transferase | |
CN107132293B (en) | Novel method for rapidly detecting EETs of brain tissues | |
JP2024513822A (en) | Separation and purification method for tetrahydrocannabivarin by high-speed countercurrent chromatography | |
JP2007240304A (en) | Fractionation apparatus | |
Goto et al. | The simultaneous determination of serum cortisol and cortisone by high-performance liquid chromatography with fluorimetric detection | |
CN112986428A (en) | N-glycosylation liquid phase analysis method of pegylated recombinant human erythropoietin | |
Baliga et al. | A simple method for desalting biological fluids for chromatography. | |
JP2000310626A (en) | Method for preparing sample for analyzing amino acid and kit for analyzing sample | |
JPS62156559A (en) | Preparation of reagent for liquid chromatography and liquid chromatography | |
JP4683172B2 (en) | Purification method of water-soluble dioxetane derivatives | |
Kinberger et al. | Determination of ethosuximide, phenobarbital, carbamazepine, carbamazepine epoxide and phenytoin in serum by high performance liquid chromatography using radially compressed columns and an aqueous methanolic mobile phase | |
JPH07243952A (en) | Method for extracting problem component from sample matrix, thin-film extraction method and method for preparing sample | |
JP2001056326A (en) | Method for refining and measuring serotonin and 5- hydroxyindole acetic acid | |
Tusell et al. | A simple extraction procedure for prostaglandins in human seminal plasma with specific detection by selected ion monitoring | |
Blondin | Analysis of the protein subunit structure of the oligomycin sensitive ATPase proteolipid fraction by reverse phase high pressure liquid chromatography | |
RU2145511C1 (en) | Method of separating mixture of fatty acid c2-c7-fraction by liquid chromatography technique | |
JP3079554B2 (en) | Synthetic DNA purification method | |
SU1068805A1 (en) | Polyhydroxicompound determination method | |
RU2180566C1 (en) | Method to release dihydroquercetin |